Novartis data at ARVO 2014 confirm transformational real world outcomes and … – MarketWatch

Novartis data at ARVO 2014 confirm transformational real world outcomes and
MarketWatch
Wet AMD: A retrospective cohort study of the injection number, associated costs and endophthalmitis rate in patients who received Lucentis or aflibercept for wet AMD in the US from November 2011 to July 2013 were reported. The US claims data showed

and more

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment